According to our (Global Info Research) latest study, the global Talacotuzumab market size was valued at US$ 75.11 million in 2025 and is forecast to a readjusted size of US$ 117 million by 2032 with a CAGR of 4.8% during review period.
Loncastuximab tesirine (trade name Zynlonta) is a humanized CD19-targeted antibody-drug conjugate (ADC). It consists of a CD19-targeted monoclonal antibody, a cleavable linker, and a pyrrolobenzodiazepine (PBD) dimer toxin. It is mainly indicated for the treatment of CD19-positive B-cell malignancies such as relapsed or refractory diffuse large B-cell lymphoma. Its mechanism of action involves the specific binding of the antibody to the CD19 antigen on the surface of tumor cells, followed by internalization into the cells and release of the toxin. The toxin induces interstrand DNA crosslinks to block DNA replication and transcription, thereby killing tumor cells. Featuring high targeting specificity and potent antitumor activity, it provides an important therapeutic option for lymphoma patients who have received multiple prior lines of therapy.In 2025, global Loncastuximab production reached approximately 7,360 vials
As one of the first CD19-targeted antibody-drug conjugates launched globally, loncastuximab tesirine holds an important position in the field of relapsed and refractory lymphoma due to its unique PBD toxin mechanism and precise targeting. However, its overall market size is constrained by its current approved indications. With a steady commercialization process, it mainly targets a niche patient population receiving later-line therapy, showing moderate market growth and focusing on consolidating its existing therapeutic position in the short term. In the competitive landscape, the drug faces intense pressure from CD19-targeted CAR-T therapies, bispecific antibodies, and similar ADCs, with its differentiated advantages lying in convenient administration and accessibility. Its long-term growth potential highly depends on the expansion to second-line and frontline indications, the development of combination therapies, and global market penetration. If key clinical progress proceeds smoothly, it is expected to break through current market constraints and further expand its share in targeted therapies for B-cell lymphoma.
This report is a detailed and comprehensive analysis for global Talacotuzumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Talacotuzumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Talacotuzumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Talacotuzumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Talacotuzumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Talacotuzumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Talacotuzumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ADC Therapeutics SA(ADCT), Overland Pharmaceuticals, Overland ADCT BioPharma (Shanghai), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Talacotuzumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
10 mg / vial
5 mg/mL
Market segment by Dosage Form
Lyophilized Powder
Reconstituted Solution
Market segment by Sales Channels
Hospitals
Retail
Online
Market segment by Application
Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
Other CD19-Positive B-Cell Malignancies
Others
Major players covered
ADC Therapeutics SA(ADCT)
Overland Pharmaceuticals
Overland ADCT BioPharma (Shanghai)
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Talacotuzumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Talacotuzumab, with price, sales quantity, revenue, and global market share of Talacotuzumab from 2021 to 2026.
Chapter 3, the Talacotuzumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Talacotuzumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Talacotuzumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Talacotuzumab.
Chapter 14 and 15, to describe Talacotuzumab sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Talacotuzumab. Industry analysis & Market Report on Talacotuzumab is a syndicated market report, published as Global Talacotuzumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Talacotuzumab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.